. . "Hlu\u0161t\u00EDk, Petr" . "2"^^ . "S" . "15" . "Homocysteine (HCY)is a risk factor for vascular diseases, cognitive impairment and dementia. Vascular diseases and cognitive impairment worsen the prognosis of Parkinson's disease. Risk of their occurence is advisable to minimize. The mechanism underlying elevated plasma HCY level is the O-methylation of levodopa. This reaction is catalyzed by the enzyme catechol-O-methyltransferase (COMT) and requires S-adenosylmethionine as the methyl donor for the production of S-adenosylhomocysteine, which is rapidly hydrolyzed to HCY. Elevated plasma HCY levels were found in PD patients treated with levodopa. Some animal studies shows., that addition of COMT inhibitors to levodopa should eliminate levodopa induced hyperhomocysteinemia (HHCY). Some of recent retrospective studies confirmed fact, but some of them did not."@en . "Vranov\u00E1, Hana" . "Ka\u0148ovsk\u00FD, Petr" . "Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients"@en . . "Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients" . "4"^^ . . "312151" . "RIV/61989592:15110/09:10224581!RIV12-MSM-15110___" . . . . . "Parkinsonism and Related Disorders" . "Langov\u00E1, Kate\u0159ina" . . "2009" . "1353-8020" . . . "L-DOPA; entacapone; Parkinson's disease; homocysteine"@en . . "RIV/61989592:15110/09:10224581" . . . "Nevrl\u00FD, Martin" . "15110" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . "[72B463EC6EA9]" . . "Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients"@en . "Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients" . . "Homocysteine (HCY)is a risk factor for vascular diseases, cognitive impairment and dementia. Vascular diseases and cognitive impairment worsen the prognosis of Parkinson's disease. Risk of their occurence is advisable to minimize. The mechanism underlying elevated plasma HCY level is the O-methylation of levodopa. This reaction is catalyzed by the enzyme catechol-O-methyltransferase (COMT) and requires S-adenosylmethionine as the methyl donor for the production of S-adenosylhomocysteine, which is rapidly hydrolyzed to HCY. Elevated plasma HCY levels were found in PD patients treated with levodopa. Some animal studies shows., that addition of COMT inhibitors to levodopa should eliminate levodopa induced hyperhomocysteinemia (HHCY). Some of recent retrospective studies confirmed fact, but some of them did not." . . "5"^^ .